share_log

We Think China Resources Medical Holdings' (HKG:1515) Healthy Earnings Might Be Conservative

We Think China Resources Medical Holdings' (HKG:1515) Healthy Earnings Might Be Conservative

我們認為華潤醫療控股(HKG:1515)的健康收益可能是保守的
Simply Wall St ·  2022/05/02 18:42

Shareholders appeared to be happy with China Resources Medical Holdings Company Limited's (HKG:1515) solid earnings report last week. Looking deeper at the numbers, we found several encouraging factors beyond the headline profit numbers.

股東們似乎對此感到滿意華潤醫療控股有限公司(HKG:1515)上週公佈穩健盈利報告。更深入地觀察這些數字,我們發現除了整體利潤數字之外,還有幾個令人鼓舞的因素。

Check out our latest analysis for China Resources Medical Holdings

查看我們對華潤醫療控股的最新分析

SEHK:1515 Earnings and Revenue History May 2nd 2022
聯交所:2022年5月2日盈利及收入歷史1515

How Do Unusual Items Influence Profit?

不尋常的項目如何影響利潤?

For anyone who wants to understand China Resources Medical Holdings' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥251m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. In the twelve months to December 2021, China Resources Medical Holdings had a big unusual items expense. As a result, we can surmise that the unusual items made its statutory profit significantly weaker than it would otherwise be.

對於任何想要了解華潤醫療控股公司超出法定數字的利潤的人來説,重要的是要注意到,在過去的12個月裏,由於異常項目,法定利潤減少了2.51億元人民幣。看到不尋常的項目讓公司損失利潤從來都不是件好事,但從好的方面來看,情況可能很快就會改善。當我們分析全球絕大多數上市公司時,我們發現重大的不尋常項目往往不會重複。畢竟,這正是會計術語所暗示的。在截至2021年12月的12個月裏,華潤醫療控股有一大筆不尋常的項目支出。因此,我們可以推測,這些不尋常的項目使其法定利潤明顯低於正常情況下的水平。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道,分析師對未來盈利能力的預測是什麼。幸運的是,您可以單擊此處查看基於他們估計的未來盈利能力的互動圖表。

An Unusual Tax Situation

不同尋常的税務情況

Having already discussed the impact of the unusual items, we should also note that China Resources Medical Holdings received a tax benefit of CN¥155m. It's always a bit noteworthy when a company is paid by the tax man, rather than paying the tax man. Of course, prima facie it's great to receive a tax benefit. However, the devil in the detail is that these kind of benefits only impact in the year they are booked, and are often one-off in nature. Assuming the tax benefit is not repeated every year, we could see its profitability drop noticeably, all else being equal. While we think it's good that the company has booked a tax benefit, it does mean that there's every chance the statutory profit will come in a lot higher than it would be if the income was adjusted for one-off factors.

在討論了這些不尋常項目的影響之後,我們還應該注意到,華潤醫療控股獲得了1.55億元人民幣的税收優惠。當一家公司是由税務人員支付的,而不是由税務人員支付的,這總是有一點值得注意的。當然了,表面上看能享受税收優惠真是太好了。然而,細節中的魔鬼是,這些福利只在預訂的那一年影響,而且往往是一次性的。假設税收優惠不是每年重複,我們可以看到,在其他條件不變的情況下,其盈利能力顯著下降。雖然我們認為該公司獲得了税收優惠是件好事,但這確實意味着,法定利潤很有可能會比收入經一次性因素調整後的水平高出很多。

Our Take On China Resources Medical Holdings' Profit Performance

我們對華潤醫療控股公司盈利表現的看法

In the last year China Resources Medical Holdings received a tax benefit, which boosted its profit in a way that might not be much more sustainable than turning prime farmland into gas fields. Having said that, it also had a unusual item reducing its profit. Based on these factors, we think that China Resources Medical Holdings' profits are a reasonably conservative guide to its underlying profitability. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example, we've discovered 1 warning sign that you should run your eye over to get a better picture of China Resources Medical Holdings.

去年,華潤醫療控股獲得了一項税收優惠,以一種可能不會比將基本農田變成氣田更可持續的方式提高了利潤。話雖如此,它也有一個不尋常的項目減少了利潤。基於這些因素,我們認為華潤醫療控股的利潤是衡量其潛在盈利能力的一個相當保守的指標。因此,如果你想更深入地研究這隻股票,考慮它面臨的任何風險是至關重要的。例如,我們發現了一個警告信號,你應該掃視一下,才能更好地瞭解華潤醫療控股。

Our examination of China Resources Medical Holdings has focussed on certain factors that can make its earnings look better than they are. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

我們對華潤醫療控股的審查集中在某些因素上,這些因素可能會讓華潤醫療控股的收益看起來比實際情況更好。但如果你有能力將注意力集中在細枝末節上,總會有更多的東西需要發現。一些人認為,高股本回報率是高質量企業的良好標誌。所以你可能想看看這個免費擁有高股本回報率的公司的集合,或內部人士正在購買的這份股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎?保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
這篇由《華爾街日報》撰寫的文章本質上是籠統的。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。簡單地説,華爾街在提到的任何股票中都沒有頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論